Recent clinical trials, such as the CodeBreaK100 phase II study, have demonstrated that Sotorasib can achieve disease control and extend progression-free survival in CRC patients harboring this specific mutation.285 Despite these advances, the response rates in CRC appear lower than those observed in NSCLC, suggesting that intrinsic differences in KRAS^G12C-driven signaling or the TME may influence therapeutic efficacy. This evidence concerns the gene KRAS and colorectal carcinoma.